Pseudomonas-Reactive Alginate Monoclonal Antibodies
|Catalog No.||Clone No.||Size|
Format: Protein G-purified antibody in phosphate-buffered saline, pH 7.4, 50% glycerol, 0.1% sodium azide.
Pulmonary infection by mucoid, alginate-producing Pseudomonas aeruginosa is the leading cause of mortality among patients suffering from cystic fibrosis. During early childhood, cystic fibrosis patients are colonized by multiple bacterial pathogens including nonmucoid P. aeruginosa. The appearance of mucoid isolates indicates progression to chronic infections. Recent evidence indicates that P. aeruginosa is most resistant to antibiotics when the infecting cells are present as a biofilm, as they appear to be in the lungs of cystic fibrosis patients.
Antigen: Sodium alginate conjugated to KLH.
Antibody Subtype: IgG1
– A: Pharmacological grade seaweed alginate.
– B: Sonicated pool of 17 whole cell serotypes (O1-O17) of P. aeruginosa.
– C: Alginate produced by P. aeruginosa strains PAO1 and PAO581. (HD Yu et al, Marshall University, Huntington, WV)
– D: Sputum samples from cystic fibrosis patients. (HD Yu et al, Marshall University, Huntington, WV)
These antibodies do not cross-react with similar polysaccharides such as amylopectin, amylose, collagen, or glycogen.
ELISA: Use at 0.5-20ug/ml with alginate on the solid phase. Working concentrations for these antibodies are dependent on the purity and concentration of alginate in samples tested.
STORAGE AND STABILITY
These antibodies are stable for at least one (1) year at -20°C. Store in appropriate aliquots to avoid multiple freeze-thaw cycles.
For in vitro investigational use only. Not for use in therapeutic or diagnostic procedures.